Skip To Main Content
Neil Barua on Muck Rack

Neil Barua

As seen in: BMJ Open, Information Age, Future Medicine, Business Age
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neil

Contact Neil, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Non-pharmacological fatigue interventions for patients with a primary brain tumour: a scoping review protocol

|
By Emma Dures, Neil Barua, Fiona Cramp, Rachael Simms-Moore
| BMJ Open Verified
Methods and analysis Scoping reviews serve as an invaluable tool when delving into emerging research areas.30 Unlike systematic or Cochrane reviews, which often focus on specific research designs like RCTs, scoping reviews cover a broader range of methods, ensuring a more comprehensive overview of the topic.17 31 This is beneficial when navigating evolving fields, such as non-pharmacological interventions for CRF in PBT patients.
Open in Who Shared View Duplicates (2) Issue with article?

Our company ServiceMax just got acquired. Here's what we learned about M&A

|
By Neil Barua
| Business Age
PTC acquired ServiceMax for $1.46 billion. CEO Neil Barua talks about how to make M&As work There was a recent EY statistic I read that said 78% of CEOs will look to conduct mergers and acquisitions (M&As) in countries geopolitically and economically aligned with their home country, this year. The report refers to this as “friendshoring”, a deglobalisation reaction to our post-pandemic challenges and uncertainties.
Open in Who Shared Issue with article?

Convection-enhanced drug delivery: prospects for glioblastoma treatment

|
By Neil Barua, Steven Gill
| Future Medicine Verified
Despite intense research focus the prognosis for patients with glioblastoma (GBM) remains poor. Median survival with maximal intervention comprising surgical resection, radiotherapy and systemic chemotherapy is reported to be less than 15 months, and only a proportion of patients are suitable for this aggressive treatment strategy [1]. The diffuse and infiltrative nature of GBM confers a number of challenges to effective treatment.
Open in Who Shared Issue with article?
See all 3 licensed articles (4 Total)